Introduction
The BM serves as a reservoir for different classes of stem cells. In addition to hematopoietic stem cells, the BM comprises a population of marrow stromal cells or MSCs. Stromal stem cells exhibit multilineage differentiation capacity, and are able to generate progenitors with restricted developmental potential, including fibroblasts, osteoblasts, adipocytes and chondrocyte progenitors. 1 Marrow stromal cells comprise a heterogeneous population of cells, including reticular endothelial cells, fibroblasts, adipocytes and osteogenic precursor cells that provide growth factors, cell to cell interactions and matrix proteins that play a role in the regulation of hematopoiesis. 1 2 originally described a population of adherent cells from the BM that were non-phagocytic and exhibited a fibroblast-like appearance. Following ectopic transplantation under the kidney capsule, these cells (CFU-F) gave rise to a broad spectrum of differentiated connective tissues including bone, cartilage, adipose tissue and myelosupportive stroma. 2, 3 On the basis of these observations it was proposed that these tissues were derived from a common precursor cell residing in the BM, termed the stromal stem cell, the BM stromal stem cell, the MSC or the skeletal stem cell. 4 MSCs secrete cytokines important for hematopoiesis and promote engraftment of hematopoietic stem cells in experimental animal models, especially when the dose of hematopoietic stem cells is limiting. [5] [6] [7] In light of the controversy as to whether MSCs at the single cell level truly fulfill the criteria of self-renewal and multilineage differentiation capacity, it was recently proposed to use the term multipotent mesenchymal stromal cells (with the acronym MSCs) to describe fibroblast-like plastic adherent cells. 8 Although the BM serves as the primary reservoir for MSCs, their presence has been reported in a variety of other tissues. These include periosteum and muscle connective tissue, 9,10 fetal BM, liver and blood. 11 There is still an ongoing debate about their presence in steady state peripheral blood, their frequency quite likely being extremely low. MSCs have been identified in cytokine (G-CSF) mobilized peripheral blood by some investigators, 12 although other studies were negative. 13 MSCs have been identified in fetal blood 15 and also in umbilical cord blood.
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14 However, other laboratories have been unable to grow MSCs from umbilical cord blood. 15 The frequency of MSCs in these sources is very low. In fetal blood, the frequency has been reported to decline with gestational age, from about 1/10 6 mononuclear cells in firsttrimester fetal blood to 0.3/10 6 mononuclear cells in term cord blood. 11 Recently, MSCs have been successfully isolated from human amniotic fluid. 16 The phenotype of the culture-expanded amniotic fluid-derived cells was similar to that reported for MSCs derived from secondtrimester fetal tissues and adult BM. At present, no unique phenotype has been identified that allows the reproducible isolation of MSC precursors with predictable developmental potential. The isolation and characterization of stromal cell function therefore still rely primarily on their ability to adhere to plastic and their expansion potential. The capacity of ex vivo expanded MSCs to differentiate into multiple mesenchymal lineages, including bone, fat and cartilage, is presently used as a functional criterion to define MSCs. 1 Currently, no specific marker or combination of markers are available to identify MSCs. Phenotypically, ex vivo expanded MSCs express a number of nonspecific markers, including CD105 (SH2 or endoglin), CD73 (SH3 or SH4), CD90, CD166, CD44 and CD29. 1 MSCs are devoid of hematopoietic and endothelial markers such as CD11b, CD14, CD31 and CD45. 1 Recently, Buhring et al.
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developed new antibodies, including W8B2 and frizzled-9 (FZD9), for the isolation of human MSCs from BM and placenta, respectively. Whether culture-expanded MSCs differ from their in vivo progeny is uncertain, as proliferation on plastic surfaces could induce both phenotypic and functional changes. 1, 18 Recently, techniques have become available to isolate and grow mesenchymal progenitors and to manipulate their growth under defined in vitro culture conditions. As a result, MSCs can be rapidly expanded to numbers that are required for clinical application. This has allowed the clinical testing of culture-expanded MSCs in the context of hematopoietic SCT (HSCT).
Standard conditions for expansion of MSCs include the presence of serum, in most instances FBS, although platelet-rich plasma is currently being evaluated as an alternative by some centers. 19 Cell density is a critical factor affecting the growth of cells. Culture attempts are usually unsuccessful below a critical cell density. The cells can be grown directly that is, unmanipulated, following collection or after density gradient separation. The EBMT consortium has developed common expansion protocols for MSCs isolated from BM to be used in its ongoing and future clinical studies.
Immunomodulatory properties of MSCs
Although it is widely accepted that MSCs give rise to cells that form the structural network in support and maintenance of normal hematopoiesis, current opinion regarding MSCs and their immune suppressive function is derived from in vitro experiments of expanded MSCs. Whether or not they play an important physiological role in the regulation of immune homeostasis remains to be determined.
Experimental models suggest that MSCs have potent immune-modulatory effects, primarily through the inhibition of effector functions, thus offering a promising option for treating immune mediated disorders including GVHD and autoimmune diseases. [20] [21] [22] [23] [24] [25] Mesenchymal stromal cells are poor Ag-presenting cells and do not express MHC class II or co-stimulatory molecules. Human BM stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli 20 and inhibit the response of naive and memory Ag-specific T-cells to their cognate peptide. 20 Accordingly, expanded MSCs do not stimulate T-cell proliferation in MLR and are able to downregulate alloreactive T cell responses when added to MLCs. 20, 21 However, in an immunocompetent host, MSCs have been shown to elicit an immune response (in the context of a murine model of reduced-intensity allogeneic SCT). 24 Human MSCs altered the cytokine secretion profile of DCs, naive and effector T cells (T helper 1 (T(H)1) and T(H)2), and natural killer (NK) cells to induce a more antiinflammatory or tolerant phenotype. [21] [22] [23] Interaction of MSCs with the tryptophan catabolizing enzyme, indoleamine 2, 3-dioxygenase, has been described. 26 However, the role of indoleamine 2, 3-dioxygenase in MSC-mediated immune suppression is not clear. Various interactions mediating the suppression of T cell proliferation have been proposed, but as yet the mechanisms remain unclear.
What is evident is that most studies demonstrate that soluble factors are involved, as the separation of MSC and PBMC by a transwell permeable membrane does not prevent the inhibition of proliferation. 20, 27 Mesenchymal stromal cells upregulate CD4 þ CD25 þ Fox P3 þ cells (T regulatory immunophenotype), 21 although their depletion has no effect on the inhibition of T cell proliferation by MSC. 22 At low NK to MSC ratios, MSCs alter the phenotype of NK cells and suppress proliferation, cytokine secretion and cytotoxicity against HLA-class I expressing targets. 23 Some of these effects require cell-to-cell contact, whereas others are mediated by soluble factors, including transforming growth factor-b1 and prostaglandin E2, suggesting the existence of diverse mechanisms for MSC-mediated NK cell suppression. On the other hand, MSCs are susceptible to lysis by activated NK cells.
The pertinent in vitro immune modulatory properties of MSCs have recently been summarized. 25 
Preclinical results
Almeida-Porada et al. 28 observed that co-transplantation of human stromal cells into pre-immune fetal sheep resulted in an enhancement of long-term engraftment of human cells in the BM and higher levels of donor cells in the circulation, both during gestation as well as after birth. Infusion of BM-derived osteoblasts promoted the engraftment of allogeneic hematopoietic stem cells in mice. 29 Other studies in non-obese diabetic/severely compromised immunodeficient mice indicate that co-transplantation of MSCs and cord blood enhances engraftment of human hematopoietic cells in the BM of non-obese diabetic/ severely compromised immunodeficient mice. 30 Co-infusion of fetal lung-derived MSCs and umbilical cord bloodderived CD34 þ cells promoted the engraftment of both myeloid and B lymphoid cells in the marrow of recipient mice, showing that the engraftment-promoting effect of MSCs was not lineage specific. 7 It was also found that enhancement of engraftment might be independent of the homing of MSCs to the marrow and might be mediated by the release of cytokines that promote either the homing or proliferation of hematopoietic stem cells.
Recently, Bartholomew et al. 31 demonstrated that MSC infusions can suppress lymphocyte proliferation and prolong skin grafts in a non-human primate.
It has been difficult to demonstrate donor engraftment of MSCs following transplantation. In some studies, gene marked culture-expanded MSCs were infused along with unmodified BM cells, and PCR evidence of marked MSCs was demonstrated in the marrow at several weeks after transplantation. [28] [29] [30] Infusion of allogeneic MSCs ameliorated lethal GVHD in mice receiving haploidentical hematopoietic stem cell transplants, but only when MSCs were administered early and repeatedly after transplantation. 32 Recently, the effects of MSCs have been reported in animal models of autoimmunity, such as amelioration of experimental autoimmune encephalitis in a murine model, raising the possibility of MSC use in autoimmune diseases. 33 However, in a collagen-induced model of rheumatoid arthritis, the infusion of MSCs did not provide any evidence of improvement. 34 
Clinical results
Animal models may not predict the clinical situation, as the immune modulatory mechanisms between species (for example, murine and human MSCs) may differ. The clinical application of ex vivo expanded MSC therapy in the HSCT setting has to date exploited their potential immune modulatory properties as well as their abilities to support hematopoietic stem cell proliferation.
Adult studies
Initial phase I studies involving BM-derived MSCs showed that MSCs could be successfully collected, culture-expanded ex vivo for 4-7 weeks and administered to patients with hematological malignancies in CR. The infusions contained up to 50 Â 10 6 MSCs and were well tolerated without adverse reactions. 13 In a subsequent phase I-II clinical trial in patients with breast cancer, autologous and expanded MSCs were coinfused with autologous PBPCs. 35 Clonogenic MSCs could be detected in venous blood up to 1 h after infusion in the majority of patients. No toxicities were observed related to the infusion of MSCs, and hematopoietic reconstitution (defined as time to neutrophil and platelet recovery) was rapid, suggesting some efficacy of MSC infusion on hematopoietic reconstitution.
In another multicenter phase I-II study, allogeneic donor BM-derived MSCs were co-infused in patients with hematological malignancies undergoing matched sibling SCT. 36 Preliminary data suggest that there was no immediate toxicity following infusion of MSCs and that there was more rapid engraftment and low incidence of acute GVHD, in comparison with historical controls. In a matched pair analysis patients receiving 1-2 Â 10 6 per kg MSCs exhibited a significantly reduced incidence of both acute and chronic GVHD. 37 Pediatric studies Inborn errors of metabolism. Mesenchymal stromal cells express high levels of arylsulfatase A and a-L-iduronidase. 38 The deficiency of these enzymes is associated with specific inborn errors of metabolism. Arylsulfatase A deficiency is the cause of metachromatic leukodystrophy, and a-L-iduronidase deficiency is the cause of Hurler's disease, disorders that may be cured by allogeneic HSCT. 38, 39 Expanded MSCs were administered to patients with metachromatic leukodystrophy and Hurler's disease, who had previously undergone HSCT but had residual symptoms of their disease. 40 Four of five patients with metachromatic leukodystrophy showed improvement in nerve conduction velocity.
MSCs have been used to treat bone disease, namely osteogenesis imperfecta. 41 Five children with osteogenesis imperfecta undergoing HSCT had donor osteoblast engraftment, with new bone formation, an increase in total bone mineral content, as well as an increase in growth velocity and noticeable reduced fracture frequencies. 42 MSCs identified by specific gene markers were given to six children undergoing HSCT for severe osteogenesis imperfecta. 43 Engraftment of MSCs was identified and this was associated with acceleration of growth velocity.
Haploidentical PBSCT. T-cell-depleted HSCT from an HLA-haploidentical relative is a feasible option for children in need of an allograft and lacking either a suitable related or unrelated donor. 44 However, both primary (failure to establish any hematological reconstitution or donor chimerism) and secondary (initial engraftment not sustained) graft failure, mainly mediated by host alloreactive T cells escaping the preparative regimen and favored by the profound T-cell depletion of the graft, have been reported to occur in up to 15-20% of transplanted children, 45 despite the infusion of large numbers of hematopoietic stem cells. 46 We recently reported the results of a phase I/II pilot study of co-transplantation of BM-derived, ex vivoexpanded MSCs of donor origin in children undergoing haploidentical HSCT with G-CSF-mobilized and CD34-selected progenitor cells. The study was carried out in two centers (Pavia and Leiden) participating in the EBMT MSC consortium, using a shared protocol and common reagents. 47 Bone marrow-derived, ex vivo-expanded haploidentical MSCs were infused, fresh or after cryopreservation, at a target dose of 1-5 Â 10 6 per kg body weight, approximately 4 h before T-cell depleted, G-CSF-mobilized positively selected CD34 þ cells from the same haploidentical donor. The target number of CD34 þ cells was 20 Â 10 6 CD34 þ cells per kg recipient weight.
Twenty consecutive unselected children were treated. Pre-transplant conditioning depended on their underlying disease, and no pharmacological GVHD prophylaxis was given after PBSCT. There were no significant differences for age, gender, transplant indication, donor type and number of CD34 þ or CD3 þ cells infused between study patients and controls. In comparison to historical controls (20% graft failure), all patients who were given MSCs engrafted successfully (P ¼ 0.03). Hematological recovery of leukocytes was faster (P ¼ 0.01) with lymphocyte rather than neutrophil recovery accounting for this. The incidence of viral reactivations did not differ significantly between patients and controls.
These demonstrated the safety and feasibility of MSC use, and that in the context of HLA-disparate transplantation, co-infusion of expanded MSCs can overcome graft dysfunction.
Cord blood. Transplantation using umbilical cord blood (UCB)-derived hematopoietic stem cells was first proposed in the 1980s and later supported by in vitro studies with human cord blood and in vivo studies with mouse models. 48 The first successful human identical UCB transplantation (UCBT), based on these preliminary findings, was carried out in 1988 in a child with Fanconi's anemia, 49 and subsequently the first unrelated donor UCBT was performed in 1993.
Unrelated donor UCBT offers many practical advantages as an alternative source of stem cells 50 including: (a) Relative ease of procurement compared with unrelated BM. 51 (b) Potential HLA matches for ethnic diverse populations. 52 
(c) Absence of risk for mother and donor. (d) Reduced risk of transmission of infection, most notably CMV. (e)
The ability to store frozen tested material with rapid delivery as required by the transplant center. 53 (f) Less GVHD. 54 However, the success of UCBT has been limited by the low yield of cells, resulting in a higher rate of graft dysfunction, as well as subsequent delayed immune reconstitution. 54 The delayed neutrophil and lymphocyte recovery has resulted in more infections in recipients of UCBT, both during and post engraftment. The overall survival rates are similar between unrelated UCBT and unrelated BMT. 55 As outcome of UCBT has been clearly shown to be dependent upon the cell dose infused, attempts have been made to increase the cell content of UCB. The Minnesota group reported on their initial findings in 23 high-risk adult patients who underwent transplantation with two partially mismatched cord blood units. 56 The preliminary results have been encouraging both as to high rates of donor engraftment and low rates of GVHD. The data supporting the transplantation of two immunologically distinct UCB units are not associated with crossed immunological rejection, but single unit predominance has been observed following this approach.
On the basis of the observation that in the murine model, co-transplantation of MSCs augments cord blood stem cell engraftment, 30 we recently reported the results of a phase I/II pilot study of co-transplantation of haploidentical third party BM-derived, ex vivo-expanded MSCs in children UCBT. The study was carried out in three centers (Pavia, Stockholm and Leiden) participating in the EBMT MSC consortium, using a shared protocol and common reagents. 57 BM-derived, ex vivo-expanded haploidentical MSCs were infused, fresh or after cryopreservation, at a target dose of 1-5 Â 10 6 per kg body weight, approximately 4 h before UCB stem cells. The available cord blood unit contained X1.7 Â 10 5 per kg recipient weight CD34 þ cells or a nucleated cell count at the time of cryopreservation X2.5 Â 10 7 per kg recipient weight. The initial seven patients (five with ALL, one each with thalassemia and hemophagocytic lymphohistiocytosis) enrolled in the study and the outcome was compared with 21 historical controls given UCBT without MSC, matched for disease and type of donor. Conditioning regimen depended on the underlying disease and GVHD prophylaxis was CsA in case of sibling donors and CsA and steroids for unrelated CBT recipients. The number of nucleated cells infused did not differ between patients and controls. Only controls received G-CSF after transplantation to accelerate neutrophil recovery. All patients and controls engrafted. In comparison to controls, the time needed to obtain neutrophil and platelet engraftment in the patient population was similar. TRM was reduced, with 24% of controls dying in the first 100 days after UCBT, whereas none of the patients experienced complications. The study is continuing to recruit patients.
Refractory severe acute GVHD. Despite advances in donor HLA typing methods (and thus donor selection) and post-transplant immune suppression, acute (a)GvHD remains a significant cause of TRM and morbidity following allogeneic HSCT, even in the matched HLAidentical sibling setting. 58 Steroids still represent first-line treatment for established GVHD with a response rate in the order of 30-50%, whereas the outcome of patients with severe steroid-refractory aGVHD remains unsatisfactory and overall survival is poor. 59 Le Blanc et al. 60 reported the successful treatment of severe steroid/treatment-resistant grade IV aGVHD of the gut and liver in a nine-year-old with haploidentical third party BM-derived MSCs.
An EBMT consortium multicenter non-randomized study addressing the infusion of MSCs from either HLAidentical stem cell donors, haploidentical family donors or unrelated HLA-mismatched donors for patients with severe steroid refractory aGVHD confirmed this observation. 61 A total of 55 patients were entered into the study of which 25 were children, aged between 0.5 and 18 years. A total of 92 MSC infusions were given with 28 patients receiving two or more infusions compared with the remaining 27 patients who received only one infusion. Patients were treated with multiple different regimens before MSC infusions were administered, and the timing of the infusions varied. Seven patients had received donor lymphocytes before the development of aGvHD. The response rates seen in this diverse cohort of severely ill patients were higher than those described earlier for patients with a similar degree of aGvHD.
Interestingly, the results were positively influenced by the inclusion of pediatric patients. Children responded consistently better than adults, for reasons that are unclear (response rate 80% in children compared with 60% in adults (P ¼ 0.28), with more CR and less progressive disease. 61 This translated into improved survival in the pediatric group. Twenty-one patients are alive with a median follow-up of 16 months (range 1.5-64) after MSC infusion. Among adults, 27% (8/30) of the patients survived compared with 52% (13/25) of the children (P ¼ 0.09).
Specific analysis of subsequent EBV and CMV reactivity in two patients included in this study cohort demonstrated that effector functions of virus-specific T-cells were retained after MSC infusion. This is an important observation, as infection is common in this highly immune-suppressed group of patients and was the cause of death in a substantial number of responders. 61, 62 Future application in pediatrics Mesenchymal stromal cell transplantation offers potential for the future and the results of phase I/II studies now pave the way for randomized studies in the future. In the prevention and treatment of aGVHD, randomized proposals by the EBMT consortium are now entering the clinical stage. The issues of dosage and timing, as well as efficacy of these novel therapies need to be addressed.
Developments within the allogeneic transplant setting, further understanding of the properties of expanded MSCs and exploiting the immune modulatory properties of MSCs offer new potential modalities of treatments for pediatric autoimmune disease refractory to standard treatments. It has been suggested that MSCs may be used in autoimmune inflammatory bowel disease not only because of their immunomodulatory effects but also because of their capacity for healing damaged gut epithelium. 60, 61, 63 Similarly, investigations into other autoimmune processes, such as juvenile rheumatoid arthritis, systematic lupus erythmatosis, dermatomyositis and type I diabetes mellitus, are in the initial phases of development.
